ADIL · Company research
Adial Pharmaceuticals, Inc (ADIL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Adial Pharmaceuticals (ADIL) Eases to $3.88 as Traders Watch $3.69 Support - Wyckoff Accumulation - https://www.dars.gov.et/ | Adial Pharmaceuticals (ADIL) Eases to $3.88 as Traders Watch $3.69 Support - Wyckoff Accumulation https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 12, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals (ADIL) Slips 1.76% to $3.90 as Shares Press Toward Lower Support - PCR Spike - https://www.siam.in/ | Adial Pharmaceuticals (ADIL) Slips 1.76% to $3.90 as Shares Press Toward Lower Support - PCR Spike https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 10, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision - The Globe and Mail | Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision The Globe and Mail | View source ↗ | The Globe and Mail | Oct 3, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027. | View source ↗ | GlobeNewswire Inc. | Sep 30, 2026 | bullish | 1 | 1 |
| Adial Pharmaceuticals (ADIL) Rises 2.72% to $4.15, Nearing Key Resistance - Leveraged ETF Flow - www.siam.in | Adial Pharmaceuticals (ADIL) Rises 2.72% to $4.15, Nearing Key Resistance - Leveraged ETF Flow www.siam.in | View source ↗ | www.siam.in | Sep 30, 2026 | neutral | 0 | 0.6 |
| A new hire's right to buy 155,446 Adial shares vests over four years. - Stock Titan | A new hire's right to buy 155,446 Adial shares vests over four years. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan | Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| A new Adial employee gets a 307,814-share option at $5.76 - Stock Titan | A new Adial employee gets a 307,814-share option at $5.76 Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Adial (ADIL) Shares: Finishes 14.56% Down at $5.31; Current Setup: the Current Price Sits Inside the Supplied Technical Range at the Close - Regression Channel - https://www.dars.gov.et/ | Adial (ADIL) Shares: Finishes 14.56% Down at $5.31; Current Setup: the Current Price Sits Inside the Supplied Technical Range at the Close - Regression Channel https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Aug 24, 2026 | neutral | 0 | 0.6 |
| Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition | ADIL Stock News - Quiver Quantitative | Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition | ADIL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 17, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support Level - Breakout Stock Alerts - dars.gov.et | Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support Level - Breakout Stock Alerts dars.gov.et | View source ↗ | dars.gov.et | Aug 7, 2026 | neutral | 0 | 0.6 |
| ADIL Forecast — Price Target — Prediction for 2027 - TradingView | ADIL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing - Yahoo Finance | Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing Yahoo Finance | View source ↗ | Yahoo Finance | Jun 16, 2026 | neutral | 0 | 0.6 |
| ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally - Stocktwits | ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally Stocktwits | View source ↗ | Stocktwits | Jun 11, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals acquires Azora Therapeutics for $32M - Investing.com | Adial Pharmaceuticals acquires Azora Therapeutics for $32M Investing.com | View source ↗ | Investing.com | Jun 11, 2026 | neutral | 0 | 0.6 |
| Adial Pharmaceuticals (ADIL) Institutional Ownership 2026 $ADIL - MarketBeat | Adial Pharmaceuticals (ADIL) Institutional Ownership 2026 $ADIL MarketBeat | View source ↗ | MarketBeat | Feb 18, 2026 | neutral | 0 | 0.6 |
| ADIL Should I Buy - Intellectia AI | ADIL Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Feb 14, 2026 | neutral | 0 | 0.6 |
| Should I buy Adial Pharmaceuticals (ADIL) - Zacks Investment Research | Should I buy Adial Pharmaceuticals (ADIL) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jan 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.